The PTCH1 gene is a human tumour suppressor gene frequently mutated in basal cell carcinoma (BCC) and several other tumour types. It encodes a receptor for soluble factors of the hedgehog family. Binding of hedgehog to the receptor relieves its inhibitory action on the transmembrane co-receptor Smoh. In this study we describe alternative first exons of the PTCH1 tumour suppressor gene and show that they are differentially regulated in normal tissues, exon 1B being expressed at very low levels and the major mRNA species containing exon 1 or 1A. Exon 1B transcripts were found to be specifically upregulated in nodular BCCs. The different PTCH1 transcripts all encode proteins that interact with Smoh in doubly transfected cells. Furthermore, functional assays demonstrated that whereas all PTCH1 isoforms can inhibit the activity of SHH, only the PTCH1B isoform is capable of fully inhibiting Smoh activity. The results indicate that in tumour cells the PTCH1B promoter is specifically activated and importantly, that the N-terminal part of PTCH1 including exon 1B is required for full inhibition of Smoh signaling but not for physical interaction with Smoh.
Introduction
PTCH1 is a human homolog of the Drosophila patched gene and similarly to its fly counterpart, it is an important determinant of pattern formation during embryonic development (Ingham, 1998) . The human homologue was originally discovered as the gene responsible for the development of the Nevoid Basal Cell Carcinoma Syndrome (NBCCS), an autosomal dominant developmental disorder characterized by multiple abnormalities and predisposition to development of basal cell carcinomas and other tumours (Hahn et al., 1996a; Johnson et al., 1996) . It was shown later that the PTCH1 gene was also mutated in at least 30% of sporadic basal cell carcinomas (Gailani et al., 1996) as well as in several other types of tumours (McGavrey et al., 1998; Vorechovsky et al., 1997a,b) . Interestingly, when PTCH1 mRNA levels were examined in BCCs, all the tumours showed upregulation of PTCH1 message (Gailani et al., 1996; Unden et al., 1997) . This is due to the autoregulatory properties of the PTCH1 gene and in most cases reflects the upregulation of abnormal PTCH1 message from the remaining mutated PTCH1 allele. However, in the cases of BCC where the PTCH1 gene is not mutated, the upregulation of the wild-type message suggests that the pathway is activated by an alternative mechanism, possibly by mutations in other pathway components. It has indeed been demonstrated that a subset of BCCs contains activating mutations in the gene encoding the PTCH1 co-receptor Smo (Xie et al., 1998) .
PTCH1 encodes a multipass transmembrane receptor for the hedgehog family of secreted factors. Its normal function appears to be inhibition of signalling via the 7-TM receptor Smoh (a homologue of Drosophila smoothened). Upon hedgehog binding the inhibitory activity of PTCH1 on Smoh is relieved resulting in transmission of the signal into the nucleus and activation of gene transcription that is mediated by the GLI family of transcription factors (homologs of the Drosophila Ci gene product) (Ruiz i Altaba, 1997) . The mechanism of PTCH1 inhibition of Smoh and its relief by SHH binding to PTCH1 is not clear; it does not appear to involve disruption of the ability for physical interaction but requires the C-terminus of Smoh (Murone et al., 1999) whereas the C-terminus of PTCH1 is dispensable (Stone et al., 1996) .
Expression of alternative first exons is a common mechanism of achieving complex patterns of tissuespecific expression in many genes (Wang et al., 1999) . In several cases no other specific functions are known to be associated with the alternative first exons which are usually noncoding. In the present study we describe three alternative first exons of the PTCH1 gene that are not only differentially regulated in normal tissues and tumours but also confer different functional properties to the PTCH1 gene product. These results strongly indicate that the N-terminal region of PTCH1 is required for full Smoh inhibition and that the major mRNA species expressed in several normal tissues encode proteins that are incapable of fully inhibiting Smoh signalling.
Results

5' RACE and RT -PCR reveal multiple differentially expressed first exons in the PTCH1 gene
Since the original studies describing the isolation of PTCH1 reported different 5' ends of the gene, we decided to examine this issue in a systematic fashion. An initial investigation using 5' RACE of mRNA from human epidermis and placenta showed the presence of several exon 1 species (data not shown). The original exon 1 reported by us was designated as exon 1 (Hahn et al., 1996a) , an additional first exon was named exon 1A (Hahn et al., 1996b) and the exon originally reported by Johnson et al. (1996) designated as 1B (Figure 1 ). Of these exons only 1B contained an ATG codon whereas exons 1 and 1A appeared to be noncoding with exon 1 containing an in-frame stop codon. Sequencing of multiple clones derived from the 5' RACE of epidermal tissue revealed only the presence of exons 1 and 1A (at about equal ratios) and an apparent absence of exon 1B expression. However, placental and lung RNA's contained exon 1 and 1B sequences (data not shown). These results indicated the existence of alternative first exons and nested PCR was used to amplify the region between exon 1 (1,1A, 1B) and exon 2 in a cDNA panel using specific primers giving products of different size. We found that the exon 1 transcript could be detected in all tissues examined and that exon 1A was absent in leukocytes but was present in all other tissues (Figure 2 ). Exon 1B was present in testis and at lower levels in the spleen, colon and ovary. The level of expression of the exon 1B transcript appeared lower than the levels of exon 1 and exon 1A in all eight tissues tested (Figure 2) . To obtain additional evidence by a non-PCR-based method for the presence of mRNAs encoding different first exons RNase protection analysis was employed using human testis as the source of RNA. Three riboprobes were generated that span 149 bases of the exon 1B, 97 bases of exon 1 or 192 bases of exon 1A. Each probe contained an additional 44 bases derived from exon 2. As anticipated, protected fragments with a size of 193 bases for exon 1B, 141 bases for exon 1 and 236 bases for exon 1A were clearly visible ( Figure  3 ) confirming the results from the PCR analysis.
To obtain evidence that differential expression at the mRNA level also results in differential protein isoform expression we performed immunostaining of human testis and human neutrophil granulocytes using both an antibody recognizing a common epitope at the Cterminus of PTCH1 (PTCH-C) and an antibody recognizing an epitope in exon 1B (PTCH-G19). Tissue from human testis shows positive reactivity for PTCH-C predominantly in the Sertoli cells and spermatocytes and with a weak signal in Leydig cells. In serial sections stained with the PTCH-G19 antibody a weaker immunoreactivity is observed in the same cells. In comparison, in human neutrophil granulocytes only the PTCH-C antibody gives rise to a significant immuno- * denotes a T to G polymorphism and nucleotides in parentheses denote insertion/deletion polymorphisms reactivity while reactivity for the exon 1B specific PTCH-G19 antibody in these cells is undetectable (Figure 4 ). This pattern of staining is in concordance with the results from analysis of mRNA, where exon 1B transcripts were present in testis but not detectable in leukocytes, and supports the conclusion that the alternative mRNAs are translated into proteins in vivo.
Increased expression of PTCH1B transcripts in BCC BCC show increased PTCH1 mRNA levels and RT -PCR analysis of RNA isolated from the nodular form of sporadic BCC was performed in order to identify the exon 1 transcripts expressed in tumour cells. Nodular BCC tissue (480% tumour cells) and adjacent normal tissue were obtained from five different patients and RT -PCR was performed using the same primers as described for the amplification of exon 1's in the cDNA panel. The levels of both exon 1 and 1A transcripts appeared similar in tumour and normal tissues, whereas the relative levels of exon 1B were increased in all tumour samples compared to exons 1 and 1A. (Figure 5 ).
PTCH1 alternative 5' mRNAs code for proteins that co-localize and interact with Smoh
The alternative first exons of PTCH1 1A and 1 did not contain a conventional ATG start codon and exon 1 contains an in-frame stop codon. However, they both contain open reading frames in-frame with exon 2 of Leukocytes. Transcripts containing exon 1 could be detected in all tissues. Exon 1A transcripts were detected in all tissues except in leukocytes. Transcript 1B was expressed in testis and at apparently lower levels in spleen, colon and ovary. The predicted RT -PCR fragment sizes are as follows: Exon 1B: 122bp, Exon 1: 141bp. Exon 1A: 192bp Figure 3 RNase protection assay for PTCH1 exon 1, 1A and 1B transcripts. Analysis of alternative PTCH1 first exons by RNase protection assay. Lanes were loaded as follows: Lane 1, exon 1, Lane 4, exon 1B and Lane 7, exon 1A undigested riboprobe. Lane 2, exon 1, Lane 5, exon 1B and Lane 8, exon 1A riboprobe incubated with 20 mg of total RNA from human testis subjected to RNase digestion. Lane 3, exon 1, Lane 6, exon 1B and Lane 9, exon 1A, riboprobe subjected to RNase digestion without added human testis RNA PTCH1 as well as alternative start codons. This raised the question whether these mRNAs can code for protein. To answer this question, expression constructs were generated containing cDNAs with each of these exons linked to the CMV promoter and transcriptional start site. These constructs also contained a FLAG epitope tag at their C-terminus for detection and were transiently transfected into 293 cells. The localization of the transfected proteins was determined by indirect immunofluorescence using antibodies against the epitope tag. As shown in Figure 6 (a -c) all of these constructs encode proteins that localizes mostly in the cytoplasm but also to the plasma membrane. Using a N-terminally myc-tagged construct also gave similar staining ( Figure 6d ). Similar observations have been reported by other researchers who have suggested that PTCH1 may internalize SHH and be involved in vesicular transport (Incardona et al., 2000) . Furthermore, when epitope tagged Smoh was transfected either alone or together with PTCH1 isoforms, it colocalized with PTCH1 to similar subcellular compartments (Figure 6e,f) .
To determine whether the PTCH1 alternative isoforms were of the correct molecular weight, the size of the transfected proteins was determined by Western blotting. As shown in Figure 7a , all PTCH1 isoforms show a similar migration pattern with a size of around 150 kd on SDS polyacrylamide gels. All of the proteins could be readily detected even though PTCH1-1B was consistently expressed at a higher level. Since PTCH1 isoforms show apparent co-localization with Smoh we next wanted to determine whether all of these isoforms could interact with Smoh as observed previously for PTCH1-1B. In this experiment FLAG-tagged PTCH1 isoforms were co-transfected with HA-tagged Smoh. The immunoprecipitation was carried out using the anti-FLAG antibody and Smoh was detected in the immune complexes by Western blotting with anti-HA antibody. As shown in Figure 7b , all PTCH1 isoforms are able to associate with Smoh.
Full inhibition of Smoh activity requires the presence of exon 1B in PTCH1
To dissect the functions of PTCH1 isoforms, we next performed functional assays utilizing the PTCH1 promoter reporter construct (Kogerman et al., 1999) . PTCH1 isoform expression constructs were co-transfected with SHH, Smoh, and GLI1 into NIH3T3 cells and the level of reporter gene activity was measured. As shown in Figure 8a , all the PTCH1 isoforms inhibit the activation of the PTCH1 promoter by SHH but not by GLI1. Remarkably, only PTCH1-1B (but not PTCH1-1 or PTCH1-1A) was able to fully inhibit reporter gene activation mediated by over-expression of Smoh. To exclude the possibility that this difference was due to different expression levels and to specifically map the Smoh inhibition response to exon 1B sequences, we performed similar experiments with Nterminally myc-tagged PTCH1 constructs with similar results (data not shown). To confirm these results by an independent method, we performed differentiation assays in C3H 10T1/2 cells with similar results (Figure  8b ). Only PTCH1-1B was able to fully inhibit the activity of Smoh whereas the other isoforms caused moderate activation of the pathway and only partial inhibition of Smoh response. These results indicate that even though all PTCH1 isoforms can interact with Smoh, exon 1B is required to fully inhibit its function.
Discussion
In this study we have described the alternative first exons of the PTCH1 tumour suppressor gene and shown that they are differentially regulated in normal tissues, exon 1B being expressed at very low levels with major mRNA species containing exons 1 and 1A. Exon 1B was specifically upregulated in nodular BCCs. The presence of all three exons was shown by the results from both a PCR based analysis and by the use of the RNase protection assay. That this expression pattern is also reflected at the protein level is supported by the finding of positive immunoreactivity in testis but not in neutrophils using an exon 1B specific antibody, whereas both cell types were positive when stained with an antibody directed towards the common Cterminus. This correspondence between mRNA analysis and immunostaining provides strong evidence that at least PTCH1 exon 1 and 1B isoforms can be translated into proteins in vivo.
Functionally, it was shown that all PTCH1 isoforms could code for proteins that co-localize and interact with Smoh in doubly transfected cells. Using functional assays we have demonstrated that whereas all PTCH1 isoforms can inhibit the activity of SHH, only the PTCH1-1B isoform is capable of fully inhibiting Smoh activity. Since the 1B isoform showed the highest expression in transfected cells, we cannot fully exclude the possibility that the observed functional differences reflect the different expression levels. However, we do not favour this possibility since all the proteins were equally effective in inhibiting response to SHH. Furthermore, some evidence has been presented in the literature (Ingham et al., 2000) that Ptc inhibits Smo by a non-stoichometric, catalytic mechanism making the inhibition less dependent on the dose of Ptc protein.
According to established views the function of alternative transcription start sites is to be able to fine-tune tissue specific regulation of gene expression via the use of alternative promoters. However, in the case of PTCH1 we observe that such alternative transcription start sites can produce proteins with different biological functions. Furthermore, the functionally most important isoform is the one that is normally expressed at the relatively lowest levels. It is interesting to note that for GLI1, which is a major transcriptional activator in the hedgehog signalling pathway, expression of transcripts with different 5' UTRs and biological potency was recently reported (Wang and Rothnagel, 2001 ) which is most likely related to a need for close control of hedgehog signalling strength and duration.
A yet unresolved question is how expression of transcripts with alternative first exons is regulated. An attractive hypothesis is that different promoters regulate the transcription of PTCH1 and allow the influence of different transcriptional regulators giving rise to a tissue and signal specific expression pattern. This issue will be addressed in future work.
We have discovered that alternative first exons confer different functions to PTCH1 protein. The next question is whether such regulatory mechanisms are conserved in evolution? When comparing the sequences of alternative first exons to the sequences in the GenBank database, it became evident that exon 1B sequences were conserved in evolution: a related sequence was present in Drosophila Ptc as well as in rodent, frog and fish homologues. The completely sequenced C. elegans genome contains multiple ptc-like genes and two of these also show homology to the PTCH1 exon 1B sequences (PTC1 and PTC3). We could not find any significant similarities to exon 1 and 1A sequences in the public databases. Whether or not the usage of alternative first exons in the PTCH1 gene is conserved in other species, remains to be established. However, exon 1 and 1A-like sequences are present in mouse genomic DNA with especially high homology in the exon 1 region (F Rahnama, P Kogerman, PG Zaphiropoulos, R Toftga˚rd, unpublished results) making it likely that alternative exon usage is conserved at least in mammals.
What is the biological role of different PTCH1 isoforms? We would like to propose that in normal tissues hedgehog signalling is held at a certain level by expression of PTCH1-1, -1A and possibly the PTCH2 protein. If this balance is shifted towards activation, however, expression of PTCH1-1B is activated and the balance restored (Figure 9 ). If the PTCH1 gene is mutated, PTCH1-1B expression is also activated but the mutant mRNA cannot produce functional protein resulting in runaway activation of the pathway and eventually tumour formation.
We know that PTCH1 containing alternative first exons can be expressed and that the gene products are functional. However, we do not know exactly where the translation of these alternative proteins starts. Exon 1 contains an in-frame stop codon and cannot contribute to the protein. Exon 1A contains several CTG codons that may function as alternative translation start sites. However, the functional equivalence of proteins containing exon 1 and exon 1A sequences would argue that even if exon 1A sequences contribute to the protein product, they are not of any functional importance that can be detected in our assays. Taken together these data make it more likely that the translation of alternative PTCH1 isoforms starts at an ATG located in exon 3.
The mechanism of Smoh inhibition by PTCH1 is presently unknown. Recent work by Scott and coworkers (Johnson et al., 2000) implicated the Cterminal cytoplasmic domain in Ptc function and showed that in Drosophila hedgehog binding and signal antagonism are separable functions of Ptc. Lack of functional importance of the extreme C-terminus of mammalian PTCH1 was shown by Stone et al. (1996) suggesting that the important domain is located in the membrane-proximal region of the C-terminal tail. More recently the importance of the Sterol Sensing Domain (SSD) has been reported (Strutt et al., 2001; Martin et al., 2001) Our data suggest functional importance also for the N-terminus suggesting a model where both the N-terminus and C-terminus of Ptc are brought into close proximity of the SSD to form a functional domain involved in Smo inhibition. Whether this model is true or not can be tested in future studies.
In summary we show that in several tissues, including skin, PTCH1 transcripts excluding the ATG-containing exon 1B are commonly expressed whereas in basal cell carcinomas exon 1B transcripts are preferentially increased. Proteins encoded by transcripts containing exons 1 and 1A are still able to efficiently inhibit a transcriptional response to SHH but lack full potency to inhibit the co-receptor Smoh. These results imply that a further level of fine-tuning of hedgehog signalling is achieved by regulated expression the hedgehog receptor PTCH1 variants encoding different N-terminal ends.
Materials and methods
RNA extraction and cDNA preparation
Samples were obtained from five specimens of nodular Basal Cell Carcinoma (BCC) and from adjacent normal human skin, lung and placenta. Total RNA in normal and tumour samples was prepared using RNAgents 1 Total Isolation System (Promega USA). Fifty milligram of tissue was homogenized with a mortar and pestle on dry ice and added to 600 ml of lysis buffer. The lysis buffer consisted of 26 mM Sodium citrate (pH 6.8), 0.5% N-lauryl sarcosine, 0.125 M bmercaptoethanol, 4 M guanidine thiocyanate. After adding 60 ml Sodium Acetate (pH 4.0) and 600 ml of Phenol : Chloroform : Isoamyl alcohol and centrifuging the total RNA was precipitated by adding an equal volume of isopropanol to the aqueous phase. The sample was incubated at 7708C overnight. The final RNA pellet was washed with 75% ethanol and dissolved in 15 ml water and the concentration was measured spectrophotometrically.
For reverse transcription Promega Reverse Transcription System (Promega, USA) was used. A mixture of 4 ml MgCl 2 (25 mM), 2 ml Reverse Transcription 106 Buffer, 2 ml dNTP Mixture (10 mM), 0.5 ml Recombinant Rnasin 1 Ribonu- Figure 9 Model for the function of different PTCH1 isoforms. On the left-hand side the normal situation in most tissues is depicted: Smoh is expressed, but its activity is held at a low level by PTCH1-1 and -1A isoforms. Activatory GLI proteins (GLIact) are not available for the target sites and target genes including PTCH1-1B are not expressed. On the right the situation is depicted when a ligand (SHH) is present. In this case the inhibition of Smoh by PTCH1 is relieved and the signal is transduced resulting in activation of target genes by activatory GLI proteins. One of the target genes being expressed is PTCH1-1B. PTCH1-1B will inhibit Smoh signaling and the balance is restored. If PTCH1 or some other downstream component of the pathway is mutated, PTCH1-1B mRNA is synthesized but it cannot make functional protein or the protein is no longer able to inhibit the pathway. This results in runaway activation of the pathway and tumour formation clease inhibitor, 0.75 ml AMV Reverse Transcriptase (15 u), 1 ml Random Primers (0.5 mg) and 10 ml of total RNA was used for each tissue sample. The mixture was incubated for 10 min in room temperature followed by incubations at 428C for 10 min, 998C for 5 min and 48C in 5 min. The single stranded cDNA was used for PCR.
5' RACE and construction of PTCH expression constructs with alternative first exons 5' RACE was performed with cDNAs from skin, lung and placenta as previously described (Zaphiropoulos and Toftga˚rd, 1996) . PCR primers were designed that amplified these isoforms and in certain cases sequences adding an N-terminal myc epitope tag and/or a C-terminal FLAG tag were added.
Since exon 1 contains a stop codon the exon 1 constructs were made starting after the stop. The full-length cDNAs were expressed under control of the CMV promoter, the expression constructs were designated PTCH-myc1B, myc1A, myc1, 1B-FLAG, 1A-FLAG and 1-FLAG. Human SHH Nterminal fragment, mouse Smoh and human GLI1 were also expressed from the CMV promoter.
RNase protection assay
From human testis Total RNA was used (Clontech). Three constructs containing PTCH1 exon 1, 1A and 1B were generated by PCR amplification (20 cycles) with Taq DNA polymerase (Promega) using as templates the exon 1, 1A and 1B expression constructs. The forward primers were PTCH1-1 Nested, PTCH1-1A, PTCH1-1B in a combination with the reverse primer PTCH1-2 Nested (Table 1) . PCR products were cloned in a pGEM-T vector system (Promega), and identity of the constructs was verified by sequencing (Cybergene AB). The constructs, containing exon 1 and 1B were linearized by SphI and NcoI (Promega), whereas the exon 1A construct was linearized by NotI and SalI (Promega). cDNAs were transcribed (MAXIscript TM , Ambion) in the presence of 32 P-labelled UTP (Amersham Bioscience, Inc.) with either SP6 polymerase (exon 1 and 1B) or T7 polymerase (exon 1A). Twenty mg of total RNA from human testis were incubated with equal amounts of the three riboprobes and subjected to RNase protection analysis following the protocol of the RPA III TM kit (Ambion). Electrophoretic separation of the riboprobes and the protected fragments was performed on a denaturing 6% acrylamide/urea gel and visualized after exposure to Fuji Super RX film.
Tissue samples
Paraffin blocks from two normal human testes and skin from a patient suffering from an inflammatory skin disease (Sweet syndrome) with predominant infiltration of neutrophil granulocytes were obtained from the Department of Pathology, Huddinge Hospital (Stockholm, Sweden) and the Department of Dermatology, Karolinska Hospital (Stockholm, Sweden), respectively.
Immunohistochemistry
Dewaxed and rehydrated sections were treated with 1% H2O2 in methanol for 30 min to exhaust endogenous peroxidase activity. Subsequently sections were submerged in 10 mM citrate buffer while being heated in a 978C water bath for 30 min. Sections were incubated overnight at +48C with 1 : 200 diluted rabbit (PTCH-C) and goat (PTCH-G19) (from Santa Cruz Biotechnology) polyclonal antibodies. The antibodies were diluted in PBS containing 0.1% BSA. After rinsing in PBS, the slides were incubated with a corresponding biotinylated antibody for 30 min. The immunoreaction was visualized with the avidin-biotin complex (DAKO) with hydrogen peroxidase as substrate and diaminobenzidine as a chromogen. Counterstaining was performed with Mayer's haematoxylin. The PTCH-G19 antibody is specific for exon 1B containing proteins. The PTCH-C antibody generated by our laboratory is an affinity purified antibody directed against the C-terminal 18 amino acids common to PTCH1 isoforms with alternative first exons.
PCR reactions from Multiple Tissue cDNA (MTC TM ) panels and BCCs
Pairs of nested primers were designed for each PTCH1 alternative first exon. The sequences of primers used are given in Table 1 . For every PCR run a mastermix on ice was prepared, by using Taq polymerase from Promega, USA. Each reaction consisted of 5 ml 106 buffer B, 8 ml dNTP-mix (1.25 mM each) 0.5 mM 5' primers from exons 1, 1A and 1B (Cybergene, Sweden), 1.0 mM 3' primer from PTCH1 exon 2 (Cybergene, Sweden), 1.0 ml Taq DNA polymerase (5 U/ml), 4 ml MgCl 2 (25 mM) in a total volume of 50 ml. Master mix, (45 ml) was pipetted into a eight St 0.5-ml eppendorf tubs on ice; 5 ml of cDNA from eight different tissues (Clontech, USA), was added to each tube. The tubes were transferred into a preheated (958C) thermocycler (Perkin Elmer), and DNA was denatured for 1 min. The PCR steps were 958C for 1 min, 548C for 1 min, 728C for 1 min, 30 cycles. The nested PCR was generated by using 0.5 ml of each PCR reaction to 49.5 ml master mix with a new set of 5' and 3' primers, using the same PCR programme for additional 30 cycles. A negative control without cDNA was run each time. Six ml of each sample was analysed on a 4% NuSieve 3 : 1 agarose gel (FMC, BioProducts, USA), with DNA visualized by EtBr staining. All PCR products were cloned and sequence verified.
Expression of PTCH1 isoforms in mammalian cells: immunofluorescence, immunoprecipitation and Western blotting
Expression constructs for PTCH1 isoforms and other pathway components were transfected into human embryonic kidney 293 cells, murine NIH3T3 cells or C3H 10T1/2 cells using Superfect (Qiagen, Germany) or in later experiments Biofect (InBio, Estonia). Immunofluorescence, immunoprecipitation and Western blotting were performed as previously described (Kogerman et al., 1999) . The polyclonal antibodies to c-myc and HA epitopes were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), the anti-FLAG M2 
Reporter gene and differentiation assays
The reporter gene assays using the PTCH1 promoter luc construct were done in NIH3T3 cells and the differentiation assays were performed in C3H 10T1/2 cells essentially as previously described (Kogerman et al., 1999) . The only change was the use of a chemiluminescent substrate for alkaline phosphatase (ready-to-use CSPD) from Tropix (Boston, MA, USA) according to manufacturer's instruction and luminometric measurement of the alkaline phosphatase activity.
